Audrito and colleagues have recently reported that SIRT1 inhibition with nicotinamide has cytotoxic activity on B-CLL cells, and that this effect requires the presence of wild type p53 [13]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.